Activation of the ERK and AKT signalling pathway predicts poor prognosis in hepatocellular carcinoma and ERK activation in cancer tissue is associated with hepatitis C virus infection.
about
EFEMP1 binds the EGF receptor and activates MAPK and Akt pathways in pancreatic carcinoma cellsPotential role of chitinase 3-like-1 in inflammation-associated carcinogenic changes of epithelial cellsHepatocellular carcinoma: Where are we?Metabolic derivatives of alcohol and the molecular culprits of fibro-hepatocarcinogenesis: Allies or enemies?Targeted therapy for hepatocellular carcinoma: novel agents on the horizonGenetic alterations in hepatocellular carcinoma: An updateInvolvement of DNA damage response pathways in hepatocellular carcinoma.Estrogen receptor-dependent genomic expression profiles in breast cancer cells in response to fatty acidsGrowth differentiation factor 15 is induced by hepatitis C virus infection and regulates hepatocellular carcinoma-related genes.Targeting Phosphatidylinositide3-Kinase/Akt pathway by BKM120 for radiosensitization in hepatocellular carcinomaSTC2 is upregulated in hepatocellular carcinoma and promotes cell proliferation and migration in vitro.Small interfering RNA (siRNA)-mediated knockdown of macrophage migration inhibitory factor (MIF) suppressed cyclin D1 expression and hepatocellular carcinoma cell proliferationHepatitis C virus sensitizes host cells to TRAIL-induced apoptosis by up-regulating DR4 and DR5 via a MEK1-dependent pathwayLiver-specific knockout of GRP94 in mice disrupts cell adhesion, activates liver progenitor cells, and accelerates liver tumorigenesis.IKVAV regulates ERK1/2 and Akt signalling pathways in BMMSC population growth and proliferationTargeted deletion of ER chaperone GRP94 in the liver results in injury, repopulation of GRP94-positive hepatocytes, and spontaneous hepatocellular carcinoma development in aged miceThe silencing of Pokemon attenuates the proliferation of hepatocellular carcinoma cells in vitro and in vivo by inhibiting the PI3K/Akt pathwayCancerous inhibitor of protein phosphatase 2A mediates bortezomib-induced autophagy in hepatocellular carcinoma independent of proteasome.Roles of the Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR pathways in controlling growth and sensitivity to therapy-implications for cancer and aging.Identification of SLAMF3 (CD229) as an inhibitor of hepatocellular carcinoma cell proliferation and tumour progression.Garlic Oil Suppressed Nitrosodiethylamine-Induced Hepatocarcinoma in Rats by Inhibiting PI3K-AKT-NF-κB Pathway.Activation of the Ras/Raf/MEK pathway facilitates hepatitis C virus replication via attenuation of the interferon-JAK-STAT pathway.Down-regulation of CMTM8 induces epithelial-to-mesenchymal transition-like changes via c-MET/extracellular signal-regulated kinase (ERK) signaling.Extracellular signal-regulated kinase 1 and 2 in cancer therapy: a focus on hepatocellular carcinoma.Klotho-beta overexpression as a novel target for suppressing proliferation and fibroblast growth factor receptor-4 signaling in hepatocellular carcinoma.Modified AS1411 Aptamer Suppresses Hepatocellular Carcinoma by Up-Regulating Galectin-14.Heat Stress-Induced PI3K/mTORC2-Dependent AKT Signaling Is a Central Mediator of Hepatocellular Carcinoma Survival to Thermal Ablation Induced Heat StressNuclear EGFR impairs ASPP2-p53 complex-induced apoptosis by inducing SOS1 expression in hepatocellular carcinomaThe MAPK MEK1/2-ERK1/2 Pathway and Its Implication in Hepatocyte Cell Cycle Control.Doxorubicin induces apoptosis by targeting Madcam1 and AKT and inhibiting protein translation initiation in hepatocellular carcinoma cells.Mechanisms of doxorubicin resistance in hepatocellular carcinomaEffects of TLR4 gene silencing on the proliferation and apotosis of hepatocarcinoma HEPG2 cells.Smad3 Sensitizes Hepatocelluar Carcinoma Cells to Cisplatin by Repressing Phosphorylation of AKT.Molecular targeted therapies in hepatocellular carcinomaImmunohistochemistry panel segregates molecular types of hepatocellular carcinoma in Brazilian autopsy cases.Vascular endothelial cells facilitated HCC invasion and metastasis through the Akt and NF-κB pathways induced by paracrine cytokines.Expression of phospho-ERK1/2 and PI3-K in benign and malignant gallbladder lesions and its clinical and pathological correlations.RNA viruses and the mitogenic Raf/MEK/ERK signal transduction cascade.An individualized prognostic signature and multi‑omics distinction for early stage hepatocellular carcinoma patients with surgical resectionAllosteric MEK1/2 inhibitor refametinib (BAY 86-9766) in combination with sorafenib exhibits antitumor activity in preclinical murine and rat models of hepatocellular carcinoma.
P2860
Q24321551-EFDE90C9-C4C0-47DC-B42D-F0411EF74D04Q24656942-6650E7C7-A2C3-479F-9EF8-3E260DE66DC0Q26765182-9162E190-8CEB-43E7-B7EA-5034A39FAF4CQ26769611-ED1D0B26-EE46-40B6-A3DF-6B3738D7C5C2Q27002288-F26D1CFA-E748-4D1E-B2F4-F2989500E278Q28073241-E2BB7C13-FCD6-4011-8964-E372BDC5F157Q33616812-69463AE1-D327-46FB-B09E-26324FD8EEDAQ33747508-BD8775FC-0955-4257-896A-71667E447FB4Q33916208-11F73EE5-B97A-4F28-BB71-B2EA18C91432Q33977001-7B832DEC-16AD-47E3-A4F1-C5E4A4268DFDQ34049143-318BCD15-FC74-40B5-98E0-5A4A75265860Q34221613-885D2402-2682-495C-83A1-C0196700A580Q34291165-7B517447-D6C3-42AB-8D95-7ED0C656ECE1Q34426580-FB33B754-D06C-4431-9C92-8FCF2DFFA2C9Q34516477-65F932D8-84B7-43C0-BE08-033E8FB1ED9FQ34529312-74DC6C13-30B3-43E3-9C66-C5AE0B0D2CD9Q34540302-0B8EBD8F-9BD2-44D8-937E-519209D182F1Q34577215-01EBCE0D-8486-4FF7-BAB2-40D9FB1D2D64Q34966603-93E16FB6-3CA9-4CA2-9F81-0A3DE1081FDAQ35077803-442A7044-EFB7-4413-849D-12049C6A36F1Q35632717-414D7919-547D-45DD-A32A-B8DC3636593EQ35689692-769DE49C-9813-48A7-B509-CEDC2F8F995BQ35874388-5ED2C1C5-8EF5-4762-BB76-F9628F33F518Q35894374-3F54E0FD-6CBB-46CF-9E65-E9779CE5DD55Q35991812-5574DEE9-A835-49E2-93C3-FD9F9651A540Q36095778-4CD2F3E2-8F36-438A-B5B1-CDD98BD74A81Q36128222-D1B6E8C3-FF36-467D-A95A-E146085CED51Q36140852-CAD1EEA8-1739-4152-85EA-E929A1350853Q36362544-B56750EE-06F6-40D6-9438-73B216FD7970Q36414381-42F5D83B-61CF-4B91-A8BC-245340377490Q36687760-5F238F72-F814-4192-9C41-C3CCB144FAF1Q36825783-8EF33614-7207-4198-BE63-97D8F62CF17BQ36847307-C0E7ECD4-ADE7-4AF1-8312-4FA02EAC35D4Q37003665-4AF859D0-DF4D-47CA-8711-D6E1837255FAQ37096712-3E921C07-2A4B-44A7-9E2A-EF0DF364D671Q37115310-131E9D8A-20C6-44EE-BB2A-643EFC60A15CQ37215137-2279180F-4D3A-4EED-9888-B2E4825E9CB0Q37247071-C351817C-84BA-4397-A806-8DF080D0FFF0Q37269227-2B71242C-A827-4637-9068-9AC1C4952637Q37285551-F5339522-3160-42C3-AC90-384445539BDE
P2860
Activation of the ERK and AKT signalling pathway predicts poor prognosis in hepatocellular carcinoma and ERK activation in cancer tissue is associated with hepatitis C virus infection.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh-hant
name
Activation of the ERK and AKT ...... h hepatitis C virus infection.
@en
Activation of the ERK and AKT ...... h hepatitis C virus infection.
@nl
type
label
Activation of the ERK and AKT ...... h hepatitis C virus infection.
@en
Activation of the ERK and AKT ...... h hepatitis C virus infection.
@nl
prefLabel
Activation of the ERK and AKT ...... h hepatitis C virus infection.
@en
Activation of the ERK and AKT ...... h hepatitis C virus infection.
@nl
P2093
P1476
Activation of the ERK and AKT ...... h hepatitis C virus infection.
@en
P2093
Georgios Charalambos Sotiropoulos
Hauke Lang
Hideo Andreas Baba
Jeremias Wohlschlaeger
Karen Steveling
Klaus Juergen Schmitz
Kurt Werner Schmid
Massimo Malago
Vito Rosario Cicinnati
P356
10.1016/J.JHEP.2007.08.018
P50
P577
2007-10-29T00:00:00Z